The costs of treating vaginal and vulval cancer in England (2009–2015)
Abstract Background Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the female reproductive system including the vagina and vul...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | BMC Public Health |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12889-020-08545-4 |
id |
doaj-c569bc2952de4ee6a12c9fea97606773 |
---|---|
record_format |
Article |
spelling |
doaj-c569bc2952de4ee6a12c9fea976067732020-11-25T03:54:37ZengBMCBMC Public Health1471-24582020-04-012011810.1186/s12889-020-08545-4The costs of treating vaginal and vulval cancer in England (2009–2015)Stephanie Stephens0Anuja Chatterjee1Victoria Coles2Robin Crawford3Pharmerit InternationalMerck Sharp & Dohme LimitedMerck Sharp & Dohme LimitedAddenbrookes Hospital, Cambridge University Hospitals NHS Foundation TrustAbstract Background Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the female reproductive system including the vagina and vulva. Whilst the incidence of vaginal cancer in the UK has remained relatively stable over the past 25 years, vulval cancer rates are increasing. A body of literature exists on the epidemiology and aetiology of vaginal and vulval cancer, but little is known about the economic burden. The objective of this study was to quantify the costs of treating these cancers on the National Health Service (NHS) in England. Methods Inpatient and outpatient episodes were derived from Hospital Episode Statistics (HES). Health Resource Group (HRG) tariffs and National Reference Costs were used to estimate the cost of treating pre-cancerous and invasive vaginal and vulval lesions in England. Results The study showed that for the 5 years from 2009/2010 to 2014/2015 the total cost associated with pre-cancerous and invasive vaginal and vulval lesions was over £14 million per year on average (95% of which was attributed to inpatient costs). Vulval cancer accounted for the largest proportion; an estimated 60% of the total cost (£8.82 million). On average 4316 patients per year in England were admitted to hospital and 912 patients attended outpatient settings for pre-cancerous and invasive disease of the vagina and vulva. Conclusion The results indicate that vaginal and vulval cancer cost the English health care system over £14 million per year. Given the causal role of HPV in a proportion of these cancers, preventative measures such as the national HPV immunisation programme have the potential to reduce the economic burden. To ensure optimal use of NHS resources, it is important that future economic evaluations of such preventative measures consider the full burden of HPV related disease.http://link.springer.com/article/10.1186/s12889-020-08545-4Human papillomavirusVaginal cancerVulval cancerRetrospectiveResource useCost |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stephanie Stephens Anuja Chatterjee Victoria Coles Robin Crawford |
spellingShingle |
Stephanie Stephens Anuja Chatterjee Victoria Coles Robin Crawford The costs of treating vaginal and vulval cancer in England (2009–2015) BMC Public Health Human papillomavirus Vaginal cancer Vulval cancer Retrospective Resource use Cost |
author_facet |
Stephanie Stephens Anuja Chatterjee Victoria Coles Robin Crawford |
author_sort |
Stephanie Stephens |
title |
The costs of treating vaginal and vulval cancer in England (2009–2015) |
title_short |
The costs of treating vaginal and vulval cancer in England (2009–2015) |
title_full |
The costs of treating vaginal and vulval cancer in England (2009–2015) |
title_fullStr |
The costs of treating vaginal and vulval cancer in England (2009–2015) |
title_full_unstemmed |
The costs of treating vaginal and vulval cancer in England (2009–2015) |
title_sort |
costs of treating vaginal and vulval cancer in england (2009–2015) |
publisher |
BMC |
series |
BMC Public Health |
issn |
1471-2458 |
publishDate |
2020-04-01 |
description |
Abstract Background Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the female reproductive system including the vagina and vulva. Whilst the incidence of vaginal cancer in the UK has remained relatively stable over the past 25 years, vulval cancer rates are increasing. A body of literature exists on the epidemiology and aetiology of vaginal and vulval cancer, but little is known about the economic burden. The objective of this study was to quantify the costs of treating these cancers on the National Health Service (NHS) in England. Methods Inpatient and outpatient episodes were derived from Hospital Episode Statistics (HES). Health Resource Group (HRG) tariffs and National Reference Costs were used to estimate the cost of treating pre-cancerous and invasive vaginal and vulval lesions in England. Results The study showed that for the 5 years from 2009/2010 to 2014/2015 the total cost associated with pre-cancerous and invasive vaginal and vulval lesions was over £14 million per year on average (95% of which was attributed to inpatient costs). Vulval cancer accounted for the largest proportion; an estimated 60% of the total cost (£8.82 million). On average 4316 patients per year in England were admitted to hospital and 912 patients attended outpatient settings for pre-cancerous and invasive disease of the vagina and vulva. Conclusion The results indicate that vaginal and vulval cancer cost the English health care system over £14 million per year. Given the causal role of HPV in a proportion of these cancers, preventative measures such as the national HPV immunisation programme have the potential to reduce the economic burden. To ensure optimal use of NHS resources, it is important that future economic evaluations of such preventative measures consider the full burden of HPV related disease. |
topic |
Human papillomavirus Vaginal cancer Vulval cancer Retrospective Resource use Cost |
url |
http://link.springer.com/article/10.1186/s12889-020-08545-4 |
work_keys_str_mv |
AT stephaniestephens thecostsoftreatingvaginalandvulvalcancerinengland20092015 AT anujachatterjee thecostsoftreatingvaginalandvulvalcancerinengland20092015 AT victoriacoles thecostsoftreatingvaginalandvulvalcancerinengland20092015 AT robincrawford thecostsoftreatingvaginalandvulvalcancerinengland20092015 AT stephaniestephens costsoftreatingvaginalandvulvalcancerinengland20092015 AT anujachatterjee costsoftreatingvaginalandvulvalcancerinengland20092015 AT victoriacoles costsoftreatingvaginalandvulvalcancerinengland20092015 AT robincrawford costsoftreatingvaginalandvulvalcancerinengland20092015 |
_version_ |
1724472737051705344 |